Is prednisone appropriate for treating hand pain and stiffness?

Oral Prednisone for Hand Pain and Stiffness

Oral prednisone (10 mg daily for 6 weeks) is appropriate and effective for hand osteoarthritis with inflammatory features (pain, stiffness, and visible soft tissue swelling), but should NOT be used routinely for all hand pain and stiffness. The key is identifying the right patient: those with inflammatory hand OA who have failed topical NSAIDs and are experiencing a disease flare-up 1.

When to Use Oral Prednisone

The decision hinges on identifying inflammatory hand osteoarthritis rather than treating all hand pain indiscriminately:

• Patient must have hand OA with inflammatory features: soft tissue swelling, erythema, or morning stiffness >30 minutes 1, 2
• Ultrasound confirmation is ideal (synovial thickening or power Doppler signal), though not always required in clinical practice 1
• Use only after topical NSAIDs have failed, as topical treatments are preferred first-line due to safety 3
• Reserve for disease flare-ups requiring short-term symptom control 1

Evidence Quality and Strength

The HOPE trial (2019) provides the strongest evidence: a well-designed RCT showing 10 mg prednisolone daily for 6 weeks reduced finger pain by 16.5 points more than placebo (on 100mm VAS scale, p=0.0007) 1. This represents a clinically meaningful improvement. The effect was seen at 6 weeks but did not persist at 3 months after stopping treatment 4, confirming this is a short-term intervention only.

The 2018 EULAR guidelines notably do NOT recommend systemic corticosteroids for hand OA, stating patients "should not be treated with conventional or biological disease-modifying antirheumatic drugs" 3. However, this guideline predates the HOPE trial. The 2020 ACR guideline addresses only intra-articular (not oral) corticosteroids for hand OA 5.

Dosing Protocol (Based on HOPE Trial)

• 10 mg prednisone orally once daily for 6 weeks
• Followed by 2-week taper (gradually reduce dose) 1
• Administer in the morning before 9 AM to minimize HPA axis suppression 6
• Take with food or milk to reduce gastric irritation 6

Safety Profile and Monitoring

The HOPE trial showed good short-term safety over 6-8 weeks 1:

• Adverse events were similar between prednisone and placebo groups
• One serious adverse event (myocardial infarction) in the prednisone group, though causality uncertain
• Most adverse events in a 2024 feasibility study were non-serious and occurred within first 4 weeks 7

Critical caveats from FDA labeling 6:

• Screen for latent tuberculosis, hepatitis B, strongyloides before starting
• Avoid in patients with systemic fungal infections
• Monitor for infection risk (immunosuppression effect)
• Check for contraindications: recent MI, active infections, uncontrolled diabetes
• Do NOT stop abruptly—must taper to avoid adrenal insufficiency

What Does NOT Work

Intra-articular corticosteroid injections show conflicting evidence:

• EULAR conditionally recommends against routine use in hand OA, though may consider for painful interphalangeal joints 3
• Meta-analysis found no significant effect of intra-articular steroids on pain or function at 4-6 weeks or 3-12 months for first carpometacarpal (thumb base) OA 4
• ACR conditionally recommends intra-articular injections for hand OA, but acknowledges lack of hand-specific evidence 5

Clinical Algorithm

1. Confirm diagnosis: Hand OA with inflammatory features (not rheumatoid arthritis or other inflammatory arthropathy)
2. Verify inflammatory signs: Soft tissue swelling, warmth, prolonged morning stiffness
3. Document failed topical therapy: Patient should have tried topical NSAIDs first
4. Screen for contraindications: Active infection, recent MI, uncontrolled comorbidities, latent TB/hepatitis B
5. If appropriate, prescribe: 10 mg prednisone daily × 6 weeks, then 2-week taper
6. Set expectations: This provides temporary relief during flare-ups, not long-term disease modification
7. Monitor: Watch for infections, hyperglycemia, mood changes during treatment
8. Plan next steps: Consider hydroxychloroquine for maintenance if patient responds and relapses 2

Common Pitfalls

• Using prednisone for non-inflammatory hand pain: Will not help mechanical OA without inflammation
• Prescribing without tapering: Risks adrenal insufficiency
• Long-term use: No evidence supports chronic prednisone for hand OA; significant side effects accumulate
• Ignoring contraindications: Particularly infection risk in immunosuppressed patients
• Using as first-line therapy: Should only follow failed topical NSAIDs per EULAR recommendations 3